Predictive value of dynamic renal resistive index (drin) for renal outcome in type 2 diabetes and essential hypertension: a prospective study

Cardiovascular Diabetology

A. Solini¹  L. Ghiadoni¹  S. Taddei¹  K. Raimo¹  M. Barzacchi¹  A. Salvati¹  R. M. Bruno² 

[1] Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa, 56124, Italy;Institute of Clinical Physiology – CNR, Via Moruzzi 1, Pisa, 56125, Italy

关键词: Microalbuminuria;    Prospective study;    Renal outcome;    Arterial stiffness;    Type 2 diabetes;    Hypertension;    Renal resistive index;   

Others  :  1208981
DOI  :  10.1186/s12933-015-0227-y

 received in 2015-03-08, accepted in 2015-05-12,  发布年份 2015

【 摘 要 】

Background

Hypertension (EH) and type 2 diabetes (T2DM) are major causes of chronic kidney disease (CKD) and identification of predictors of CKD onset is advisable. We aimed to assess whether dynamic renal resistive index (DRIN), as well as other markers of systemic vascular damage, are able to predict albuminuria onset and estimated glomerular filtration rate (eGFR) decline in patients with T2DM or EH.

Methods

In this prospective observational cohort study, 27 T2DM and 43 EH patients, free of CKD at baseline, were followed-up for 4.1 ± 0.6 years. Resistive Index (RI), endothelium-dependent (FMD) and independent vasodilation in the brachial artery (after glyceryl trinitrate – GTN - 25 μg s.l.), carotid-femoral Pulse Wave Velocity (PWV), Augmentation Index (AIx), DRIN (%RI change after GTN 25 μg s.l.) were evaluated.

Results

Patients developing microalbuminuria were older, more frequently T2DM, with higher UACR at baseline, and showed higher DRIN (−2.8 ± 6.7 vs −10.6 ± 6.4 %, p = 0.01) and PWV (9.9 ± 1.3 vs 7.9 ± 1.5 m/s, p = 0.004) at baseline. The best predictors of microalbuminuria onset were DRIN > −5.16 % in T2DM (sensitivity 0.83, specificity 0.80) and PWV > 8.6 m/s in EH (sensitivity 0.96, specificity 1.00). Individuals whose eGFR declined (n = 27) had higher eGFR at baseline, but similar vascular characteristics; however in EH showing eGFR decline, baseline DRIN and PWV were higher. PWV showed a steeper progression during follow-up in patients developing albuminuria (Visit-outcome interaction: p = 0.01), while DRIN was early compromised but no further impaired (Visit-outcome interaction: p = 0.04).

Conclusions

PWV and DRIN are able to predict microalbuminuria onset in newly diagnosed EH and T2DM. DRIN is early compromised in T2DM patients developing microalbuminuria.

【 授权许可】

   
2015 Bruno et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al.. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888):260-72.
• [2]Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ et al.. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380(9854):1662-73.
• [3]Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS et al.. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81.
• [4]van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A et al.. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011; 79(12):1341-52.
• [5]Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014; 63(2 Suppl 2):S39-62.
• [6]Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al.. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21):2588-605.
• [7]Virdis A, Ghiadoni L, Versari D, Giannarelli C, Salvetti A, Taddei S. Endothelial function assessment in complicated hypertension. Curr Pharm Des. 2008; 14(18):1761-70.
• [8]Ghiadoni L, Bruno RM, Stea F, Virdis A, Taddei S. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep. 2009; 11(3):190-6.
• [9]Katakami N, Osonoi T, Takahara M, Saitou M, Matsuoka TA, Yamasaki Y et al.. Clinical utility of brachial-ankle pulse wave velocity in the prediction of cardiovascular events in diabetic patients. Cardiovasc Diabetol. 2014; 13:128. BioMed Central Full Text
• [10]Won KB, Chang HJ, Kim HC, Jeon K, Lee H, Shin S et al.. Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes. Cardiovasc Diabetol. 2013; 12:41. BioMed Central Full Text
• [11]Ford ML, Tomlinson LA, Chapman TP, Rajkumar C, Holt SG. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension. 2010; 55(5):1110-5.
• [12]Upadhyay A, Hwang SJ, Mitchell GF, Vasan RS, Vita JA, Stantchev PI et al.. Arterial stiffness in mild-to-moderate CKD. J Am Soc Nephrol. 2009; 20(9):2044-53.
• [13]Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K et al.. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care. 2011; 34(12):2570-5.
• [14]Ikee R, Kobayashi S, Hemmi N, Imakiire T, Kikuchi Y, Moriya H et al.. Correlation between the resistive index by Doppler ultrasound and kidney function and histology. Am J Kidney Dis. 2005; 46(4):603-9.
• [15]Krumme B. Renal Doppler sonography–update in clinical nephrology. Nephron Clin Pract. 2006; 103(2):c24-8.
• [16]Derchi LE, Leoncini G, Parodi D, Viazzi F, Martinoli C, Ratto E et al.. Mild renal dysfunction and renal vascular resistance in primary hypertension. Am J Hypertens. 2005; 18(7):966-71.
• [17]Hamano K, Nitta A, Ohtake T, Kobayashi S. Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients. Diabetes Care. 2008; 31(9):1853-7.
• [18]Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F et al.. Intrarenal resistive index after renal transplantation. N Engl J Med. 2013; 369(19):1797-806.
• [19]Chirinos JA, Townsend RR. Systemic arterial hemodynamics and the "renal resistive index": what is in a name? J Clin Hypertens. 2014; 16(3):170-1.
• [20]Bruno RM, Daghini E, Landini L, Versari D, Salvati A, Santini E et al.. Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes. Diabetologia. 2011; 54(9):2430-9.
• [21]Bruno RM, Rossi L, Fabbrini M, Duranti E, Di Coscio E, Maestri M et al.. Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors. J Hypertens. 2013; 31(7):1456-64.
• [22]Bruno RM, Bianchini E, Faita F, Taddei S, Ghiadoni L. Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovascular ultrasound. 2014; 12:34. BioMed Central Full Text
• [23]Gemignani V, Bianchini E, Faita F, Giannarelli C, Plantinga Y, Ghiadoni L et al.. Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol. 2008; 34(3):385-91.
• [24]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12.
• [25]Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ et al.. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol. 2013; 61(15):1626-33.
• [26]Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010; 53(11):2312-9.
• [27]Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012; 1(1):8-15.
• [28]Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N et al.. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380(9844):807-14.
• [29]Peralta CA, Weekley CC, Li Y, Shlipak MG. Occult chronic kidney disease among persons with hypertension in the United States: data from the National Health and Nutrition Surveys 1988–1994 and 1999–2002. J Hypertens. 2013; 31(6):1196-202.
• [30]Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T et al.. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012; 380(9854):1649-61.
• [31]Nosadini R, Velussi M, Brocco E, Abaterusso C, Carraro A, Piarulli F et al.. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria. Diabetes. 2006; 55(1):234-9.
• [32]Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008; 51(5):714-25.
• [33]Siddiqi FS, Advani A. Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes. 2013; 62(11):3647-55.
• [34]Mule G, Cottone S, Cusimano P, Palermo A, Geraci C, Nardi E et al.. Unfavourable interaction of microalbuminuria and mildly reduced creatinine clearance on aortic stiffness in essential hypertension. Int J Cardiol. 2010; 145(2):372-5.
• [35]Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res. 2004; 27(7):471-7.
• [36]Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011; 58(5):839-46.
• [37]O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005; 46(1):200-4.
• [38]Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G et al.. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011; 29(9):1802-9.
• [39]Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F et al.. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012; 35(10):2061-8.
• [40]Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension. 2005; 45(6):1042-9.